The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography

被引:104
作者
Nielsen, VG [1 ]
Gurley, WQ [1 ]
Burch, TM [1 ]
机构
[1] Univ Alabama, Dept Anesthesiol, Birmingham, AL 35249 USA
关键词
D O I
10.1213/01.ANE.0000123012.24871.62
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Fibrinogen has been shown to be responsible for most protein-mediated clot strength via thrombelastography. However, factor XIII (FXIII) activity also plays a prominent role in the development of clot strength. Thus, we hypothesized that changes in FXIII activity would significantly increase clot strength. FXIII (0%, 1%, 6.25%, 12.5%, 25%, 50%, and 100% normal activity) was placed in a fixed volume of citrated FXIII-deficient plasma with 1% tissue factor and calcium chloride and underwent thrombelastography for 10 min. We measured the variables reaction time (R; a measurement of clot initiation), alpha (a measure of the rate of clot formation), amplitude (A; a measure of clot strength), and shear elastic modulus (G; a measure of clot strength). FXIII activity significantly decreased R in a pattern of exponential decay (R-2 = 0.77; P < 0.001). FXIII activity significantly increased a, following a sigmoidal pattern (R-2 = 0.88; P < 0.001). Finally, increases in FXIII activity significantly increased A and G in a sigmoidal pattern (R-2 = 0.89; P < 0.001). We concluded that FXIII significantly affects R, alpha, A, and G. Thus, transfusion decision making with protein-mediated thrombelastographic patterns must account for the contribution of both fibrinogen and FXIII.
引用
收藏
页码:120 / 123
页数:4
相关论文
共 13 条
[1]   Thromboelastograph assay for measuring the mechanical strength of fibrin sealant clots [J].
Glidden, PF ;
Malaska, C ;
Herring, SW .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2000, 6 (04) :226-233
[2]   Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified Thrombelastograph [J].
Greilich, PE ;
Alving, BM ;
Longnecker, D ;
Carr, ME ;
Whitten, CW ;
Chang, AS ;
Reid, TJ .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1999, 13 (01) :58-64
[3]   Use of heparinase modified thrombelastography in liver transplantation [J].
Harding, SA ;
Mallett, SV ;
Peachey, TD ;
Cox, DJ .
BRITISH JOURNAL OF ANAESTHESIA, 1997, 78 (02) :175-179
[4]   Endogenous heparin-like substances significantly impair coagulation in patients undergoing orthotopic liver transplantation [J].
Kettner, SC ;
Gonano, C ;
Seebach, F ;
Sitzwohl, C ;
Acimovic, S ;
Stark, J ;
Schellongowski, A ;
Blaicher, A ;
Felfernig, M ;
Zimpfer, M .
ANESTHESIA AND ANALGESIA, 1998, 86 (04) :691-695
[5]   Use of abciximab-modified thrombelastography in patients undergoing cardiac surgery [J].
Kettner, SC ;
Panzer, OP ;
Kozek, SA ;
Seibt, FA ;
Stoiser, B ;
Kofler, J ;
Locker, GJ ;
Zimpfer, M .
ANESTHESIA AND ANALGESIA, 1999, 89 (03) :580-584
[6]   Monitoring platelet glycoprotein IIb/IIIa fibrin interaction with tissue factor-activated thromboelastography [J].
Khurana, S ;
Mattson, JC ;
Westley, S ;
ONeill, WW ;
Timmis, GC ;
Safian, RD .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1997, 130 (04) :401-411
[7]   Targeted inactivation of the mouse locus encoding coagulation factor XIII-A: Hemostatic abnormalities in mutant mice and characterization of the coagulation deficit [J].
Lauer, P ;
Metzner, HJ ;
Zettlmeissl, G ;
Li, M ;
Smith, AG ;
Lathe, R ;
Dickneite, G .
THROMBOSIS AND HAEMOSTASIS, 2002, 88 (06) :967-974
[8]  
LOEWY AG, 2001, HEMOSTASIS THROMBOSI, P233
[9]   Thromboelastography for monitoring prolonged hypercoagulability after major abdominal surgery [J].
Mahla, E ;
Lang, T ;
Vicenzi, MN ;
Werkgartner, G ;
Maier, R ;
Probst, C ;
Metzler, H .
ANESTHESIA AND ANALGESIA, 2001, 92 (03) :572-577
[10]   Thromboelastography with heparinase in orthotopic liver transplantation [J].
Pivalizza, EG ;
Abramson, DC ;
King, FS .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1998, 12 (03) :305-308